Starris: Optimax Space Systems and Lawrence Livermore National Laboratory (LLNL) have entered a commercialization partnership for LLNL’s patented monolithic telescope technology, which accelerates rapid deployment of modular optical designs for high-resolution or high-sensitivity space imagery.

Starris has collaborated over the last decade with LLNL’s Space Program to develop the monolithic telescope technology and will manufacture — at scale and with customization options — the precision-fabricated optical lens that forms the image in the telescope. The collaboration with LLNL is now extended via a government-use license for commercializing the technology through LLNL’s Innovation and Partnerships Office (IPO).

It was a laser shot for the ages. By achieving fusion ignition on December 5, 2022, LLNL proved that recreating the “fire” that fuels the sun and the stars inside a laboratory on Earth was indeed scientifically possible.

The achievement of ignition cemented LLNL’s position as a center of science and technology research directly relevant to inertial fusion energy (IFE) while sharpening the scientific community’s focus on developing this potentially clean, safe, enduring source of electricity for the world.

This story was originally published in the July 2024 edition of the American Nuclear Society magazine Nuclear News.

Technology designed to aid on-the-field diagnostics for military applications is gaining a wider reach as Lawrence Livermore National Laboratory (LLNL) and BioVind, LLC achieved a milestone in their partnership: the exclusive licensing of LLNL pathogen diagnostics technology focused on oil and gas applications.

The technology, called BioID, is a rapid and portable molecular diagnostics platform that can detect up to 18 target DNA or RNA sequences from a single sample in 30 to 60 minutes. BioID uses an isothermal amplification technique to detect pathogen nucleic acid.